KELLY COLONELLO: Open Payments
NPI 1952396442 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$742 in 24 payments from 12 companies in 2025. Trend: 2023 $1,006 · 2024 $569 · 2025 $742
Food & beverage: $742
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $184 |
| GlaxoSmithKline, LLC. | 4 | $113 |
| Genmab U.S., Inc. | 3 | $98 |
| Sumitomo Pharma America, Inc. | 2 | $58 |
| ABBVIE INC. | 3 | $57 |
| Eisai Inc. | 3 | $56 |
| Astellas Pharma US Inc | 2 | $52 |
| Verastem, Inc. | 1 | $28 |
| Merck Sharp & Dohme LLC | 1 | $27 |
| Baxter Healthcare | 1 | $26 |
Products named: LYNPARZA, Tivdak, JEMPERLI, MYFEMBREE, Lenvima, Veozah, EPKINLY, AVMAPKI FAKZYNJA CO-PACK.
Industry payments across AZ — which companies pay providers there.
